Core Insights - Jazz Pharmaceuticals announced improved outcomes for adults with narcolepsy or idiopathic hypersomnia treated with Xywav, as demonstrated in the Phase 4 DUET study [1][2] - The company is committed to addressing neurological disorders with limited treatment options, emphasizing the importance of ongoing data generation for Xywav and Epidiolex [3] Xywav Treatment Insights - The Phase 4 DUET trial showed statistically significant improvements in Epworth Sleepiness Scale (ESS) scores, reduced sleep stage shifts, increased deep sleep, and fewer awakenings in adults with narcolepsy treated with Xywav [2] - In adults with idiopathic hypersomnia, Xywav treatment also resulted in improvements in ESS and Idiopathic Hypersomnia Severity Scale scores [2] - Patient-reported data indicated that Xywav treatment was associated with improvements in daytime symptoms and cognitive complaints among adults with narcolepsy or idiopathic hypersomnia [2] Epidiolex Treatment Insights - A novel analysis of real-world Epidiolex treatment patterns revealed a nearly 70% (69.9%) probability of persistence at one year among new patients, highlighting the importance of dose optimization [5] - The analysis indicated that 52% of patients were taking dosages greater than 15 mg/kg/day at 12 months, with those on average dosages greater than 20 mg/kg/day having the lowest likelihood of discontinuation [5] Upcoming Presentations - Jazz Pharmaceuticals will present seven abstracts at the 2025 AAN Annual Meeting, focusing on the effectiveness and safety of Xywav and real-world data on Epidiolex [1][4]